BIOMAT Database Logo BIOMAT Database Logo

Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. 1992

R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
Department of Medicine, State University Hospital, Groningen, The Netherlands.

We studied the effects of symptomatic, antiproteinuric treatment with NSAID's (n = 28) and ACE-inhibitors (n = 14) in patients with proteinuria due to idiopathic membranous glomerulopathy (MGP). These two treatment groups were compared with a group of patients who did not receive antiproteinuric medication (n = 14). Urinary protein loss was effectively lowered by NSAID and ACE inhibitor therapy from 9.5 +/- 1.0 to 4.5 +/- 0.5 g/day (mean +/- SEM) and from 9.8 +/- 1.4 to 3.9 +/- 0.7 g/day respectively, whereas the control group showed a slight fall in proteinuria from 6.9 +/- 0.8 to 5.5 +/- 0.8 g/day. As a result of this treatment hypoalbuminaemia and hypercholesterolaemia improved significantly: serum albumin rose in the NSAID group from 25.4 +/- 1.2 to 29.0 +/- 1.0, and in the ACEi group from 29.9 +/- 1.8 to 32.7 +/- 1.2 g/l (control group from 27.4 +/- 1.6 to 27.8 +/- 1.6 g/l, while cholesterol was lowered in the NSAID group from 8.5 +/- 0.5 to 7.5 +/- 0.4 and in the ACEi group from 8.7 +/- 0.5 to 7.6 +/- 0.4 mmol/l (control group from 9.7 +/- 1.1 to 8.5 +/- 1.0 mmol/l). The antiproteinuric effect of both drugs was well maintained during an 18-month follow-up. Progression towards end-stage renal failure was observed especially in patients with impaired renal function at entry. Remission of proteinuria occurred particularly in patients with lower baseline values of proteinuria, irrespective of the treatment modality.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents

Related Publications

R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
[Clinical course in 51 patients with idiopathic membranous glomerulopathy].
March 1989, Revista medica de Chile,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
Hypocomplementemic idiopathic membranous glomerulopathy.
March 1981, Human pathology,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
Erythrocytes associated with idiopathic membranous glomerulopathy.
August 1979, Clinical nephrology,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
Treatment of idiopathic membranous glomerulopathy.
March 1994, Current opinion in nephrology and hypertension,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
[Recurrence of idiopathic membranous glomerulopathy].
October 1990, Casopis lekaru ceskych,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
Membranous glomerulopathy associated with idiopathic hypereosinophilic syndrome.
March 2010, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
[Idiopathic membranous glomerulopathy with immunologic tubular involvement].
January 1986, L'union medicale du Canada,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
Glomerular deposits in idiopathic membranous glomerulopathy.
January 1980, Archives of pathology & laboratory medicine,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
[Immunosuppressive therapy for idiopathic membranous glomerulopathy].
April 1998, Nederlands tijdschrift voor geneeskunde,
R T Gansevoort, and J E Heeg, and R Vriesendorp, and D de Zeeuw, and P E de Jong
Corticosteroid therapy is beneficial in adults with idiopathic membranous glomerulopathy.
May 1982, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!